[Progress of Immunotherapy Mechanisms and Current Evidence of PD-1/PD-L1 
Checkpoint Inhibitors for Non-small Cell Lung Cancer with Brain Metastasis].

Brain metastasis (BM) is a common complication in non-small cell lung cancer (NSCLC), which associates with poor prognosis. Recently, immune checkpoint inhibitors (ICIs) has revolutionized the treatment of tumors. Programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors could produce antitumor effect by activating the autoimmune system. The immunotherapy has already show to have a promising outcome for NSCLC patients with BM, while...